Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) rose 4.3% on Friday . The company traded as high as $25.26 and last traded at $25.11, with a volume of 68,704 shares. The stock had previously closed at $24.08.

BPMC has been the subject of a number of analyst reports. Raymond James Financial Inc. initiated coverage on shares of Blueprint Medicines Corp. in a report on Friday, May 27th. They set an “outperform” rating and a $23.00 target price for the company. Zacks Investment Research upgraded shares of Blueprint Medicines Corp. from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a report on Thursday. Canaccord Genuity initiated coverage on shares of Blueprint Medicines Corp. in a report on Friday, August 5th. They set a “buy” rating and a $26.00 target price for the company. Cowen and Company reiterated a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday. Finally, TheStreet upgraded shares of Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a report on Friday, July 29th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $29.43.

The company’s market capitalization is $676.08 million. The stock has a 50-day moving average price of $21.03 and a 200-day moving average price of $18.39.

Blueprint Medicines Corp. (NASDAQ:BPMC) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.03. The company earned $7.07 million during the quarter, compared to the consensus estimate of $4.41 million. The business’s revenue was up 163.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.81) earnings per share. On average, analysts anticipate that Blueprint Medicines Corp. will post ($2.98) EPS for the current year.

In other news, CEO Jeffrey W. Albers sold 17,000 shares of the business’s stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $22.86, for a total value of $388,620.00. Following the sale, the chief executive officer now directly owns 76,494 shares in the company, valued at approximately $1,748,652.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

An institutional investor recently raised its position in Blueprint Medicines Corp. stock. RS Investment Management Co. LLC raised its position in Blueprint Medicines Corp. (NASDAQ:BPMC) by 17.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 740,310 shares of the company’s stock after buying an additional 109,878 shares during the period. RS Investment Management Co. LLC owned about 2.73% of Blueprint Medicines Corp. worth $19,500,000 as of its most recent filing with the SEC.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.